These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27423646)

  • 1. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review.
    Kalra S; Singh V; Nagrale D
    Adv Ther; 2016 Sep; 33(9):1502-18. PubMed ID: 27423646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sodium-glucose cotransporter-2 inhibitors on renal handling of electrolytes.
    Meena P; Bhargava V; Bhalla A; Rana D; Mantri A
    Postgrad Med J; 2021 Dec; 97(1154):819-824. PubMed ID: 33563713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tubular hypothesis of nephron filtration and diabetic kidney disease.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats.
    Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2021 May; 320(5):F761-F771. PubMed ID: 33645318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
    Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
    Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M; Cherney DZ
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
    Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
    Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.
    Speedtsberg ES; Tepel M
    Front Endocrinol (Lausanne); 2023; 14():1281107. PubMed ID: 38174341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
    Toyoki D; Shibata S; Kuribayashi-Okuma E; Xu N; Ishizawa K; Hosoyamada M; Uchida S
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F826-F834. PubMed ID: 28679589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
    Nazari S; Mirkhani H
    Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockout of Na
    Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
    Hou YC; Zheng CM; Yen TH; Lu KC
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review.
    Yaribeygi H; Sathyapalan T; Maleki M; Jamialahmadi T; Sahebkar A
    Life Sci; 2020 Jan; 240():117090. PubMed ID: 31765648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.